According to OpenAI on X, the company launched its Life Sciences model series as a research preview for qualified customers, including Amgen, Moderna, the Allen Institute, and Thermo Fisher Scientific, accessible through ChatGPT, Codex, and the API (source: OpenAI, Apr 16, 2026). As reported by OpenAI, the preview targets biopharma and research workflows such as target discovery, sequence analysis, protocol generation, and literature synthesis, creating opportunities to accelerate R&D cycle times and reduce wet-lab iteration via AI-assisted reasoning and code generation within regulated environments. According to OpenAI, enterprise access through the API enables integration into ELN and LIMS pipelines, positioning these models for use cases like experiment planning, assay optimization, and data QC at scale for life sciences organizations.